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ABSTRACT Bevacizumab is a humanized monoclonal antibody against vascular endo-
thelial factor (VEGF) that targets tumor cell angiogenesis and proliferation. Although it 
is usually well tolerated, many side-effects have been reported. These include hyper-
tension, bleeding, and thromboembolic events among others. Drug-associated cuta-
neous adverse effects are less common and include itching, exfoliative dermatitis, and 
acneiform eruptions. A man with bevacizumab-associated monomorphic skin eruption 
successfully was treated with 30% salicylic acid peels. To the author’s knowledge, this 
is the first report of open comedones with no further inflammatory acne lesions that 
developed in a patient treated with bevacizumab. Complete remission of the rash was 
achieved after performing 30% salicylic peels, and the patient continued the chemo-
therapy as planned with no need of either dose reduction or discontinuation of beva-
cizumab.
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INTRODUCTION
Bevacizumab is a recombinant humanized mono-
clonal antibody that targets vascular endothelial 
growth factor (VEGF). It has been approved for the 
treatment of advanced non-small cell lung cancer, 
breast cancer, colorectal cancer, and renal cell car-
cinoma (1). The most commonly observed adverse 
events are mucosal bleeding, stomatitis, thromboem-
bolism, and disturbed wound healing (2). Cutaneous 
reactions are limited and typically include itching, ex-
foliative dermatitis, skin dryness, and acneiform skin 
rash resembling that seen after the administration of 
epidermal growth factor receptor (EGFR) antagonists 
(3-5). We report a case of sudden onset of multiple 
monomorphic open comedones on the scalp in a 
patient diagnosed with metastatic lung cancer who 
was recently started on bevacizumab. The patient 
was consequently treated with repeated 30% salicylic 
acid (SA) peels until complete disappearance of the 
skin lesions.
CASE REPORT
A 56-year-old man with a history of hypertension 
and hyperlipidemia was diagnosed with lung ad-
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enocarcinoma and supraclavicular and mediastinal 
lymph nodes metastasis in June 2014. He was started 
on treatment with carboplatin, pemetrexed, and be-
vacizumab. After three months in treatment and the 
third cycle of chemotherapy, the patient developed 
rapidly progressive lesions on the scalp.
Physical examination revealed multiple mono-
morphic open comedones on the scalp and forehead 
(Figure 1). There were no inflammatory nodules, pap-
ules, or pustules. Further physical examination was 
unremarkable.
The patient was treated with 5 sessions of 30% SA 
peel every 15 days. He continued the chemotherapy 
with no dose interruption. Clinical photographs were 
taken to assess the response. Significant improve-
ment was observed even after the first treatment 
(Figure 2). Complete remission was achieved after the 
third session, and we performed two more sessions 
post resolution of the skin lesions (Figure 3). After 3 
month follow-up, no recurrence was observed.
DISCUSSION
Vascular endothelial growth factor is a highly spe-
cific mitogen for vascular endothelial cells and the 
major driver of tumor angiogenesis described to date 
(6). It induces endothelial proliferation, promotes cell 
migration, and inhibits apoptosis. Consequently, inhi-
bition of VEGF signaling abrogates the development 
of a wide variety of tumors through reduction of the 
number of the endothelial cells and the quantity of 
micro-capillaries in the tumor tissue (3).
Several therapies that target specific components 
of the VEGF signaling pathway have been approved 
for clinical use. Bevacizumab (a humanized VEGF 
monoclonal antibody) received its first approval in 
2004 for combination use with standard chemother-
apy for metastatic colon cancer and has since then 
been approved for use in lung, renal, and ovarian 
cancers (7). Its use has been reported in dermatologic 
conditions such as metastatic melanoma (8), keratitis-
ichthyosis-deafness syndrome, and cutaneovisceral 
angiomatosis with thrombocytopenia syndrome (9).
Although bevacizumab is generally well toler-
ated, many side-effects have been reported, such as 
hypertension, hemorrhage, thromboembolic events, 
congestive heart failure, impaired wound healing, 
and infusion-related hypersensitivity reactions (2,10). 
In comparison with anti-EGFR monoclonal antibod-
ies, bevacizumab causes less frequent and less severe 
cutaneous side-effects. These include itching, exfolia-
tive dermatitis, skin dryness, and acneiform skin rash. 
Recently reported cutaneous manifestations include 
cutaneous lupus erythematosus, hand eruption, scalp 
ulceration, and perforating dermatosis (11).
There are reports in the literature describing the 
occurrence of acneiform skin rash after the infusion 
of bevacizumab, which mainly consisted of papules, 
pustules, and inflammatory nodules (4,5). Sometimes 
comedonal lesions were also present. It has been 
shown that VEGF is a growth factor for follicular cells 
and keratinocytes in addition to endothelial cells 
Figure 1. Initial clinical presentation revealed monomorp-
hic open comedones.
Figure 2. Significant improvement after the first treatment 
with 30% salicylic acid peel.
Figure 3. Complete remission after the third 30% salicylic 
acid peel.
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(12). Therefore, we can speculate that the skin erup-
tion described may occur by follicular obstruction 
and subsequent inflammation through a mechanism 
similar to that in EGFR inhibitor drug associated rash. 
This typically acneiform rash was usually treated with 
topical or oral antibiotics and topical retinoids (13). 
In the present case, our patient had a unique clinical 
presentation with multiple monomorphic open com-
edones on the scalp and forehead, and no further in-
flammatory acne lesions were observed, as would be 
expected in rashes after the administration of VEGF 
or EGFR inhibitor drugs.
Since SA has proven effective in comedonal acne, 
and no inflammatory lesions were present, we decid-
ed that it would be the preferred treatment for our 
patient. SA is a lipophilic beta-hydroxy acid possess-
ing keratolytic, comedolytic, anti-inflammatory, and 
antibacterial properties. At concentrations between 
20% and 30%, it is used for superficial chemical peels 
and removes intercellular lipids that are covalently 
linked to the cornified envelope surrounding corni-
fied epithelioid cells (14). Its indications include acne 
vulgaris, melasma, post inflammatory hyperpigmen-
tation, and photoaging. There is a recent study that 
presented repeated SA peels as an alternative treat-
ment for sebaceous hyperplasia (15). The effects of 
salicylic acid above described may be responsible for 
the extremely satisfactory results of the 30% SA peels 
in the successful treatment of the multiple open com-
edones of our patient without requiring discontinua-
tion of bevacizumab.
CONCLUSION
To the best of our knowledge, monomorphic 
open comedones have not been described before as 
the only cutaneous manifestation in a patient treated 
with bevacizumab. We propose a successful thera-
peutic approach with SA peels. 
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